Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly announces once-weekly exenatide trial results

Eli Lilly announces once-weekly exenatide trial results

9th June 2008

Eli Lilly, Amilyn Pharmaceuticals and Alkermes have announced the results of a trial comparing the efficiency of Byetta (exenatide) injection to that of a once-weekly long-acting release formulation of exenatide.

According to the findings of the 30-week study, type two diabetes patients treated with the investigational once-weekly therapy showed statistically significant improvements in glycemic control and weight.

These patients saw improvements in A1C and fasting plasma glucose from baseline and compared with Byetta, with 77 per cent of patients showing an A1C of seven per cent or less.

Daniel J Drucker, professor in the division of endocrinology in the Department of Medicine of Toronto and Director of the Banting and Best Diabetes Centre, said: “We know that a substantial number of type two diabetes patients are overweight and conventional diabetes therapies, while controlling blood glucose, may have little or no beneficial impact on body weight.”

He added that the results of the Duration-1 study presented to the annual scientific sessions of the American Diabetes Association suggest the beneficial impact of continuous levels of exenatide administered once-weekly.

In September 2007, Eli Lilly announced the results of a one-year study assessing the use of exenatide injection with insulin glargine in type two diabetes patients, with patients in the former group showing improved glycemic control and beta-cell function weight.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.